Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
4 Bijay Agrawal (CFO), Jaidit Singh Brar (CEO), Jayesh Doshi (Whole-time Director), J.S. Gujral (Managing Director)
Analysts
15 Achal Lohade, Aniruddha Joshi, Archit Shah, Bharat Shah, Bhavik Mehta, Bhavya Gandhi, Keyur Pandya, Mayank Pandey, Neel Mehta, Praveen Sahay, Rahul Maheshwary, Santhosh Seshadri, Sumant Kumar, Tanay Shah, Vishal Goel
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹1,604 crores | +67% YoY; broad-based growth with no one-time items; led by consumer (34% mix), automotive (24%), exports and ODM |
| Exports | ₹387 crores (~24% of revenue) | +61% YoY vs 40% growth in FY26; US ~22%, Europe ~40%, NAM (incl. Mexico/Canada) ~15% additional |
| ODM Revenue | ₹270 crores (~17% of revenue) | +115-120% YoY from ₹125 crores in Q1 FY26; healthcare/defense/consumer-led; long-term target 25% of sales |
| Order Book | ₹6,770 crores | As of June-end; ~₹5,400 crores executable in next 12 months; mix: consumer 30%, automotive 29%, industrial 24%, healthcare 7%, IT & railways 9% |
| Operating EBITDA | ₹162 crores | +69% YoY; Q1 margin 10.1% vs 11.3% in Q4 FY26, impacted by higher consumer mix |
| Total EBITDA (incl. other income) | ₹177 crores | +72% YoY |
| EBT | ₹141 crores | +110% YoY |
| PAT | ₹106 crores | +112% YoY |
| Net Working Capital Days | 71 days | Up from 63 days; driven by higher inventory held as strategic asset for supply assurance |
| Cash & Investments | ₹800+ crores (net cash ₹122 crores) | Short-term borrowings increased ~₹340 crores in quarter to fund strategic inventory buildup |
| Adjusted Annualized RoCE | 20.1% | Reflects continuing improvement in capital productivity |
| Customer Concentration | Top 5: 38%; Top 10: 51%; Top 20: 66% | Consistent with prior quarters; 18 new clients onboarded in Q1 |
| Capacity Utilization | 65-70% | Expansions ongoing at Bangalore, Pune, and Jodhpur (MedTech) |
| CapEx | ₹90 crores (Q1), incl. ₹50 crores for PCB | FY27 ex-PCB capex guided at ₹100-150 crores |
Geographic & Segment Commentary
- Consumer: Largest vertical at 34% of revenue; healthy growth from faster customer ramp-ups and front-loaded schedules from key customers; telecom and water-purification ODM contributed. Management expects annualized mix of ~30-32% despite Q1 seasonal aberration.
- Automotive: 24% of revenue; strong momentum from increasing EV penetration across vehicle platforms, charging-infrastructure uplift, and deeper new-customer engagement. Auto exports crossed ₹120 crores in FY26; 5 new auto clients onboarded in Q1.
- Industrial: Sequential moderation due to rear-ended maritime/defense schedules (H2-loaded) and lower smart-metering pickup; ex-defense revenue was ~₹325 crores in Q1 vs ~₹320 crores in Q4 FY26. Fuel-injection systems and utility metering are growing; order book at 24% of total provides medium-term visibility.
- Healthcare (incl. MedTech): Maintained healthy performance with ~₹500 crores order book; two new CDMO/design clients onboarded. MedTech subsidiary (Syrma Johari) did ~₹210 crores in FY26 and is expected to grow ~50% in FY27; healthcare guided at ~7-8% of FY27 revenue.
- IT & Railways: Scaling well from a lower base; C-DAC approval supports domestic server-motherboard design and manufacturing; IT assembly business growing fast.
- Exports: ₹387 crores (+61% YoY, ~24% of revenue); led by industrial, MedTech, RFID, and auto; management targets ₹1,500-1,600 crores for FY27 (30-40% growth).
- ODM: ₹270 crores (~17% of revenue), up 115-120% YoY; margin profile superior to non-ODM; short-term mix target 18-19%, long-term 25% as MedTech and defense scale.
Company-Specific & Strategic Commentary
- Kaga JV: Formed 60:40 JV with Japanese MNC Kaga for exclusive EMS manufacturing in India; combined initial investment ~₹24-25 crores. Targets Kaga's Indian automotive and AC/white-goods requirements with ₹300-500 crores revenue potential over 3-5 years, plus strategic entry into Japan's electronics ecosystem and component-distribution benefits.
- PCB Manufacturing Project: Phase I cost ~₹400 crores; building 65-70% complete, equipment arriving from October, power-on in Jan-Mar 2027, commercial production by April 2027. 50% government capex subsidy available; expected 1-1.5x gross asset turns and 15-18% EBITDA ex-PLI at full ramp-up; year-one utilization 40-50%.
- Supply Chain War Room: Senior-level war room formed to monitor every component shortage; inventory treated as strategic asset for next 1-2 quarters. Industry inventory days expected to rise until supply normalizes by end of calendar 2026.
- New Customer Engine: 18 new clients onboarded in Q1 (5 auto, 3 industrial, 2 healthcare, balance telecom/IT/railways), representing potential ₹1,000+ crores incremental revenue at full ramp-up (FY28-29); typical ramp-up gestation 12-30 months.
- Semiconductor/ISM 2.0: Management interested in assembly, backend, and PCB components under ISM 2.0, but entry is contingent on finding a credible partner; discussions ongoing, no commitment made.
- Data Center Foray: Early-stage entry into data center ecosystem (power management, cooling) with dedicated capacity being set up at Bangalore; expected to scale significantly in coming years.
- Defense: Elcome acquisition (~6 months old) serves as platform; 25-35% growth expected, with management evaluating additional technologies/offerings beyond Elcome's existing portfolio.
- ESG: Awarded EcoVadis gold medal (top 5 percentile globally); signed SBTi for 10-year emission-reduction targets; president-level executive oversees ESG.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth FY27 | 35%+; likely to be exceeded | Confident of exceeding guidance after strong Q1; only constraint is supply chain, not demand |
| EBITDA Margin FY27 | 10.5%-11% | Factors in supply-chain costs, strategic inventory, and consumer-mix seasonality |
| Exports FY27 | ₹1,500-1,600 crores (30-40% growth) | Continued global supply-chain integration; West Asia geopolitics is key variable |
| Consumer Mix | ~30% of revenue on annualized basis | Q1 was 34%; quarterly seasonality expected |
| Healthcare Mix FY27 | ~7-8% of revenue | MedTech growing ~50% on lower base; ₹500 crores order book |
| Medium-Term Growth (FY28-FY30) | 30-35% annually | Driven by new customer ramp-ups, exports, EV, and data centers |
| ODM Share | 17-19% near-term; 25% long-term | ODM needs to grow 50-60% to reach 25% while base business also scales |
| PCB Project | Commercial production by April 2027 | Equipment power-on Jan-Mar 2027; year-one utilization 40-50%, EBITDA ~10% initially |
| Supply-Chain Normalization | End of calendar 2026 | Per manufacturers/distributors; inventory days to remain elevated industry-wide until then |
| New Customer Revenue Potential | ₹1,000+ crores incremental at full ramp-up | From 18 Q1 clients; meaningful revenue from FY28-29 |
| Kaga JV Revenue | ₹300-500 crores over 3-5 years | Little contribution in current year; initial focus on Kaga's India requirements |
| CapEx FY27 | ₹100-150 crores ex-PCB | PCB Phase I funded via internal accruals, 50%+ debt, and government capex subsidy |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Supply-Chain Disruption | Middle East tensions are affecting specialty chemicals for PCB manufacturing and component lead times; AI-driven semiconductor demand is tightening supply. Management has set up a war room and is holding strategic inventory, but further escalation could disrupt the entire industry; normalization expected only by end-CY2026. |
| Percentage-Margin Compression from Pass-Through Pricing | Component/memory price inflation is passed through with no markup, so percentage margins compress even as absolute margins hold (e.g., chip moving ₹60→₹100 changes gross margin from 40% to ~28.6% on same absolute value). FY27 EBITDA margin guidance of 10.5-11% incorporates this effect. |
| Smart Metering Slowdown | Lower uptake in the Indian smart-metering business, with management deliberately restraining growth to control working capital; prolonged weakness could weigh on the industrial segment. |
| Working Capital / Cash Flow Pressure | Strategic inventory buildup added ~₹340 crores to short-term borrowings; if supply-chain disruption persists beyond expectations, elevated working capital could pressure returns. Net cash of ₹122 crores and ₹800+ crores treasury provide a buffer. |
| Demand Timing / Concentration Risk | Maritime/defense business is rear-ended into H2, and 66% of revenue comes from top 20 customers; any customer schedule pushout could skew quarterly phasing despite full-year visibility. |
| Semiconductor Entry Execution Risk | ISM 2.0 participation requires a credible partner in a capital-intensive, fast-technology-changing industry; management will not rush and risks missing an attractive window if partner selection drags. |
Q&A Highlights
No One-Time Revenue; QIP Is Enabling
- Question: Was there any one-time revenue booked in Q1? Any color on the ~₹1,000 crores QIP board resolution? (Aniruddha Joshi, ICICI Securities)
- Answer: Management confirmed no one-time items — growth came from high-margin exports, ODM (up over 100%), and consumer scale-up. The QIP is an annual enabling resolution to keep a war chest for opportunities (e.g., semicon); no immediate fundraise planned. On FY27, MD said they are on track to achieve and likely exceed guidance, with more clarity after one more quarter; the only constraint is supply-side, not demand. (J.S. Gujral, Bijay Agrawal)
Pass-Through Pricing Physics
- Question: Will memory-price increases be a complete pass-through with no margin impact? (Aniruddha Joshi, ICICI Securities)
- Answer: Absolute margins are protected by 100% pass-through, but percentage margins compress because no markup is earned on the input-price increase — a chip moving ₹60→₹100 sold at ₹100→₹140 reduces gross margin from 40% to ~28.6% on the same absolute value. No impact on absolute profit figures. (J.S. Gujral)
PCB Project Funding and Economics
- Question: How will the PCB project be funded? What asset turns and EBITDA margins should be expected? (Mayank Pandey, Emkay Global; Bhavik Mehta, JPMorgan)
- Answer: Phase I cost ~₹400 crores, with ₹100-150 crores already funded; balance via 50-60% debt, internal accruals, and 50% government capex incentive. The ₹800+ crores treasury is sufficient for all phases; Phase II/III start only in late-2027/early-2028. At 80%+ utilization, asset turns reach ~1.5x; year-one utilization of 40-50% implies EBITDA of ~10% or less, rising to 15-18% ex-PLI at full ramp-up. (Bijay Agrawal, J.S. Gujral)
FY27 Guidance Integrity and Margin Floor
- Question: With order book flat around ₹6,700 crores, should the current run-rate simply continue? Is 10.1% the margin floor given the higher consumer mix? (Keyur Pandya, ICICI Prudential Life Insurance)
- Answer: The order book has grown steadily (₹5,400 crores in Q1 FY26 to ₹6,770 crores now), with quarterly intake of ~₹1,800 crores. Revenue growth guidance of 35%+ for FY27 stands and may be exceeded. Margins will vary with mix — consumer was 34% in Q1 vs 30-32% typical — but the full-year EBITDA margin guidance of 10.5-11% is maintained. (J.S. Gujral, Bijay Agrawal)
Healthcare/MedTech Momentum and ISM 2.0
- Question: Healthcare has run at ₹130-135 crores for two quarters; what is the order book and growth outlook? Any update on PLI 2.0/ISM 2.0? (Sumant Kumar, Motilal Oswal Financial Services)
- Answer: Healthcare order book is ~₹500 crores, including RFID and MedTech; two new CDMO/design clients were onboarded. MedTech subsidiary grew to ₹210 crores in FY26 and is expected to grow ~50% in FY27; healthcare should be ~7-8% of total revenue. On ISM 2.0, management is interested in assembly, backend, and PCB components, but requires a credible partner before committing — discussions continue. (Bijay Agrawal, J.S. Gujral)
Kaga JV Opportunity Size and Order Book Duration
- Question: What is the average order execution period? How large can the Kaga opportunity be? (Bhavya Gandhi, Bajaj Alternate Investment Management)
- Answer: ~₹5,400 crores of the ₹6,770 crores order book executes in the next 12 months; average execution period is ~10.5 months. The Kaga JV initially caters exclusively to Kaga's India automotive and AC/white-goods requirements (little in the current year), with ₹300-500 crores revenue potential over 3-5 years; strategically, it opens the door to Japan's conservative electronics ecosystem and provides component-distribution leverage. (Bijay Agrawal, J.S. Gujral)
Supply-Chain Risk to Guidance; Industrial Ex-Defense
- Question: With supply-chain disruptions and bare-PCB shortages, is there risk to FY27 guidance? What does industrial look like ex-defense? (Tanay Shah, DAM Capital)
- Answer: MD sees no micro-level risk to demand or execution — meeting/exceeding guidance is a "tough chase" but on track. The only imponderable is further West Asia escalation hitting global supply capacity. A dedicated war room monitors critical components, and inventory is stocked to support deliveries. On industrial, Q4 FY26 defense maritime contributed ₹140 crores of ₹460 crores; ex-defense was ~₹320 crores in Q4 and ~₹325 crores in Q1, with smart meters deliberately moderated for working capital control while fuel-injection and utility metering grow. (J.S. Gujral, Bijay Agrawal)
Sustaining 30-35% Growth; Data Centers and Export Drivers
- Question: Can 30-35% growth continue given the rising base? Which segments outgrow, and how broad-based is export traction? (Santhosh Seshadri, Avendus Spark)
- Answer: Management guided 30-35% growth for the next 2-3 years on a higher base; global clients onboarded in 2025-26 will contribute meaningfully in FY28-29. Accelerants include EV automotive and charging, exports (industrial, MedTech, IT), and an early-stage data-center power/cooling opportunity with dedicated Bangalore capacity. Even faster growth is possible given the scale of global customers, but management won't commit until series supplies begin. Export composition is currently concentrated in industrial, MedTech, and RFID, with auto expected to rise. (J.S. Gujral)
ODM and Export Trajectory
- Question: How will ODM and export contributions trend, and what are their margin profiles? (Praveen Sahay, PL Capital)
- Answer: Exports guided to ₹1,500-1,600 crores (30-40% growth) in FY27 on last year's
₹1,200 crores; ODM momentum (100% growth) should continue as MedTech and defense scale. Both carry superior margins. ODM mix is 17% today, moving to 18-19% short-term and 25% long-term, which requires ODM to grow 50-60% while the base business also grows; ODM is concentrated in healthcare, defense, consumer, and some industrial. (J.S. Gujral)
JV and Customer Evaluation Criteria; Ramp-Up Gestation
- Question: What are the top criteria for JV partners, what do partners see in Syrma, and what is the customer ramp-up and wallet-share trajectory? (Rahul Maheshwary, Ambit Investment Advisors)
- Answer: JVs/acquisitions must bring technology, market access, or regulatory approvals — pure revenue-adds are avoided. Ramp-up takes ~12-18 months for mature transferred products and 18-30 months for new products requiring validation. With global customers, Syrma starts at 1-2% wallet share, moving to 4-6% over 5-7 years (which can still be $50-100 million given their scale); domestically, Syrma is typically #1 or #2 vendor and works to widen the gap. (J.S. Gujral)
Defense Scaling and Working Capital Intent
- Question: Is the elevated working capital built into the growth confidence, and how does defense scale beyond Elcome's existing portfolio? (Archit Shah, 360 ONE Capital)
- Answer: Higher borrowings reflect a conscious 1-2 quarter strategic inventory decision for fast customer ramp-ups (especially consumer) and supply constraints — not structural. Defense is early-stage (Elcome acquired ~6 months ago); management expects 25-35% growth and plans to add technologies and offerings beyond Elcome's menu over the next 3-5 years. (Bijay Agrawal, J.S. Gujral)
Key Takeaway
Syrma SGS delivered a strong Q1 FY27: revenue of ₹1,604 crores (+67% YoY), operating EBITDA of ₹162 crores (+69%), and PAT of ₹106 crores (+112%), with management confirming no one-time items. Growth was broad-based — consumer (34% of mix) and automotive (24%) led, exports rose 61% to ₹387 crores (24% of revenue), and ODM nearly doubled to ₹270 crores (17% of revenue). Strategically, the company formed a 60:40 JV with Japan's Kaga (₹300-500 crores potential over 3-5 years), kept the ₹400 crores PCB project on track for April 2027 commercial production, and onboarded 18 new clients with ₹1,000+ crores ramp-up potential. Management guides FY27 revenue growth of 35%+ (likely exceeded), EBITDA margin of 10.5-11%, and exports of ₹1,500-1,600 crores, with 30-35% growth sustained over 3-5 years. Key watch points are West Asia supply-chain escalation, percentage-margin compression from pass-through pricing, and securing a credible ISM 2.0/semiconductor partner.